Abstract. T-type calcium channels are involved in a variety of physiological and pathophysiological processes, and thus could be therapeutic targets. However, there is no T-type channel selective blocker for use in clinical practice, demanding a need for the development of novel drugs where a higher-throughput screening system is required. Here we present pharmacological studies on Ca v 3.1 T-type channels using automated patch-clamp. The IC 50 values obtained from automated patch-clamp and conventional one showed a good correlation (correlation coefficient of 0.82), suggesting that the automated patch-clamp is an efficient and reliable method for ranking the drug potencies for T-type channels.
T-type calcium channels are present in nerve tissues, heart, smooth and skeletal muscles, and endocrine tissues, involved in neuronal excitability, cardiac pacemaker activity, smooth muscle contraction and hormone secretion (Perez-Reyes 2003) . Neuronal T-type calcium channels in particular have been suggested to play a vital role in regulation of sleep (Anderson et al. 2005) , nociception (Kim et al. 2003) , epilepsy (Tsakiridou et al. 1995) and neuropathic pain (McCallum et al. 2003) , thus becoming an attractive target for such disorders. Indeed, T-type calcium channel blockers have been demonstrated to be effective for treatment of cerebral diseases such as absence epilepsy (Vitko et al. 2005) , epilepsy (Khosravani et al. 2005 ) and neuropathic pain (Flatters 2005) . Mibefradil, a specific blocker of T-type calcium channels had been used for therapeutic treatment of hypertension and angina pectoris (Clozel et al. 1990 ). However, mibefradil is metabolized by cytochromes P450 3A4 and 2D6 with other drugs and interacts with them pharmacokinetically, which results in various adverse effects including irregular heart rhythms (Krayenbuhl et al. 1999) . As a result, mibefradil has been withdrawn from the market so that a selective blocker for T-type calcium channels for clinical use is not available, waiting for the development of T-type calcium channel specific drugs.
For ion channel drug discovery, patch-clamp measurements have been the gold-standard assay. However, the conventional patch-clamp is not suitable for effective screening in early stages of drug discovery due to its timeconsuming and labor-intensive nature. Recent developments of automated patch-clamp devices are rapidly utilized for ion channel drug discovery as well as safety pharmacology such as cardiac toxicity tests using hERG channels (Dunlop et al. 2008) . Numerous research papers on assessments of cardiac hERG channel liability with various automated patch-clamp devices have been reported (Bridgland-Taylor et al. 2006; Ly et al. 2007) , revealing that the automated patch-clamp is reliable for ranking the potencies of drugs. However, Ttype calcium channels have not been rigorously tested using automated patch-clamp except for a brief case study on Ca v 3.2 T-type calcium channels ). Thus, pharmacological studies on T-type calcium channels with automated patch-clamp would be valuable due to urgent needs for developments of T-type calcium channel specific drugs for clinical use. In the present work, recombinant Ca v 3.1 T-type calcium channels were studied using auto-mated patch-clamp, where four independent patch-clamp measurements can be conducted in parallel.
To characterize pharmacological properties of Ca v 3.1 Ttype calcium channels, whole-cell currents were recorded A B C nels were studied from whole-cell currents evoked by the test pulses of -20 mV for 50 ms at a holding potential of −100 mV. On average, 1 μM mibefradil inhibited the peak currents of Ca v 3.1 channels by 63 ± 4% (n = 5). Five concentrations of mibefradil (0.001 μM to 10 μM) were applied to the patched cells in a cumulative fashion as shown in the representative time trace of the peak currents of Ca v 3.1 channels in Fig. 1A .
Further pharmacological studies on Ca v 3.1 channels were carried out using the chemically diverse drugs known to block T-type calcium channels (see Supplementary material, Fig. S1 ). The inhibition of Ca v 3.1 peak currents by all of the examined blockers was concentration-dependent (Fig. 1B) . Normalized peak current amplitudes in the presence of each drug were plotted as a function of drug concentration and fitted to a Hill equation. The concentration required for 50% inhibition (IC 50 ) was summarized in Table 1 . For comparison, the IC 50 values of each drug for Ca v 3.1 channels were also obtained using conventional patch-clamp (see Supplementary material, Fig. S2 ), which exhibited the similar values to those obtained with automated patch-clamp (Table 1) . Overall, pharmacological data showed a good agreement between the two methods; a correlation coefficient (R) of 0.82 and a slope of 0.96 ± 0.05 were determined by a linear regression (open circles and solid line in Fig. 1C) . A decent correlation was also observed in the comparison between the automated patch-clamp results and the reported values; R of 0.70 and a slope of 0.85 ± 0.09 (filled squares and dashed line in Fig. 1C) .
For pharmacological studies of Ca v 3.1 channels with automated patch-clamp, the sealing rate was good (>80%); gigaseals onto the cell were mostly formed once the cells were attached ( Fig. 2A) . However, the rate for obtaining the whole-cell configuration was reduced to 43% with the mean initial membrane resistance (R wc ) of 1.66 ± 0.12 GΩ (median value of 710 MΩ, n = 390, Fig. 2B ). The overall success rate of getting usable recordings was further dropped to 16% partly due to lack of functional channel expression, which is evident in the mean peak amplitude of Ca v 3.1 channel currents of -169 ± 7 pA (median value of -130 pA, n = 395), ranged from -20 to -1160 pA (Fig. 2C) .
For the past five years, the developments of automated patch-clamp electrophysiology have been widely adapted in drug discovery (for reviews see Dunlop et al. 2008) . The number of papers on ion channel studies using automated patch-clamp have been rapidly accumulated, where most studies compare the potencies of blockers and/or agonists obtained from automated patch-clamp to the values measured with conventional one, showing a good agreement.
T-type calcium channel specific drugs for clinical use need to be developed in a timely fashion, in which higherthroughput screening with automated patch-clamp techniques is necessary. The automated patch-clamp studies on T-type calcium channels would thus provide the valuable data for usage of an automated patch-clamp platform for such drug discovery. T-type calcium channels were previously studied with recombinant Ca v 3.2 T-type calcium channels using automated patch-clamp for the basic biophysical properties ), but this study did not provide pharmacological data. To rigorously characterize pharmacological properties of T-type calcium channels with automated patch-clamp, we focused on Ca v 3.1 channels, one of the three isoforms of T-type calcium channels. Various blockers with diverse chemical structures were tested against Ca v 3.1 channels to validate the ability of automated patch-clamp for ranking the drug potencies. The IC 50 values obtained with automated patch-clamp are in good agreement with those determined with conventional patch-clamp (R of 0.82) as well as the published data (R of 0.70). A better correlation was observed with the values obtained in the present study than with the previously reported values, which is probably due to the differences in experimental conditions such as recording solutions and voltage protocols. The underestimated IC 50 values previously often observed due to the limited time for solution exchange and the adsorption of lipophilic test compounds (Guo and Guthrie 2005; Sorota et al. 2005) were not observed in the present work. Also, the range of the IC 50 values extends over six orders of magnitude of concentrations with a slope of 0.96 determined by a linear regression, close to the unity line, indicating that the dynamic range of this method is broad enough for most of the test compounds to fall into this range. Thus, our pharmacological data with various drugs suggest that T-type calcium channels could be well studied using automated patch-clamp in a fast and reliable fashion. The experimental throughput of an automated patchclamp method has been reported to be increased by 5-to 45-fold over conventional patch-clamp (Brown 2009; ). In the present work, the automated patch-clamp increases throughput of roughly 4-fold compared to conventional patch-clamp mainly due to the relatively low overall success rate of getting usable patches in Ca v 3.1 channel recordings, which could be a potential drawback for screening purposes. In contrast to conventional patch-clamp, where cells are manually selected for patchclamping, cell selection is random in automated patch-clamp recordings. The low overall success rate may thus be partly caused by the small size of cells randomly selected, leading to the reduced current amplitudes. This problem could be solved by generating improved recombinant cell lines. Other cell lines such as Chinese hamster ovary (CHO) cells rather than HEK293 cells may express sufficiently measurable currents, thus being more compatible and robust with automated patch-clamp experiments (Clare et al. 2009 ). Indeed, the overall success rates in automated patch-clamp mainly depend on the combination of the cell line chosen and ion channels expressed, and CHO cells have been suggested to be a better choice than HEK293 cells to obtain the high success rates in automated patch-clamp experiments (Dunlop et al. 2008; ). Another way to maximize the current amplitude is to optimize the cell preparation conditions and/or to change the composition of the patch solutions ). Using non-enzymatic cell dissociation solutions instead of trypsin for cell detachment may be less harsh on cells, thus Statistics of whole-cell recordings of Ca v 3.1 channels in automated patch-clamp. A. Success rates presented as % of cells that meet the criteria for each defined stage: seal rate (n = 912, defined as 100%), whole-cell access obtained (n = 395, 43%), and channel expression (n = 146, 16%). B. Cell population distribution of initial membrane resistances (R wc ) for cells expressing Ca v 3.1 channel in automated patch-clamp (mean resistance of 1.66 ± 0.12 GΩ and median value of 710 MΩ, n = 390) with a Gaussian distribution fit (mean of 396 ± 27 MΩ). C. Population histogram showing the cell distribution of the peak currents of Ca v 3.1 channels ranged from -20 to -1160 pA in automated patch-clamp (mean amplitude of -169 ± 7 pA and median value of -130 pA, n = 395) with a Gaussian distribution fit (mean of -125 ± 6 pA).
A B C
enhancing channel currents since proteases could affect the current amplitudes (Rajamani et al. 2006) . Modifying the composition of recording solutions, for example, adding cAMP into the intracellular solution may increase calcium currents because it has been known that PKA (cAMP-dependent protein kinase A)-mediated phosphorylation of Ca v 3.1 T-type calcium channels stimulates channel activity (Chemin et al. 2007 ), thus supposedly inducing enhancement in calcium currents.
In conclusion, the present work demonstrates that blockers of T-type calcium channels can be screened more efficiently and reliably using automated patch-clamp techniques. Drug potencies of T-type calcium channels obtained with both automated and conventional methods were similar, which is an important and useful feature for drug screening. Overall, given the significance of T-type calcium channels as drug targets, automated patch-clamp recordings of Ca v 3.1 channels could provide an alternative way for higher-throughput screening for novel drug discovery targeted against T-type calcium channels.
Human embryonic kidney 293 (HEK293) cells stably expressing human Ca v 3.1 T-type calcium channels along with the Kir2.1 inward rectifier potassium channels were obtained from the Korea Research Institute of Bioscience and Biotechnology. Since inward rectifier potassium channels lower the resting membrane potential, the HEK293 cell line coexpressing inward rectifier potassium channels was used to prevent cell damage due to the unwanted calcium influx during cell culture ). Cells were cultured in Dulbecco's modified Eagle's medium containing 10% (v/v) fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 μg/ml) as well as selection antibiotics, geneticin G418 (200 μg/ml) for α 1G and puromycin (1 μg/ml) for Kir2.1 in humidified 5% CO 2 at 37°C. Cells were passaged every three days by treatment with trypsin-EDTA. For automated patch-clamp recordings, cells were plated into the 100-mm culture dishes. Cells at 50-80% confluency were harvested by treatment with trypsin-EDTA, washed twice and resuspended in the extracellular solution at a final cell density of 1-5 × 10 6 cells/ml. For conventional patch-clamp recordings, cells were seeded onto the poly-L-lysine coated glass cover slips. Whole-cell patch-clamp experiments were carried out 24-48 h after seeding.
Automated patch-clamp electrophysiology
The automated patch-clamp device, NPC-16 Patchliner (Nanion Technologies, Germany) was used for whole-cell recordings. Whole-cell currents were recorded with the intracellular solution containing (in mM): 50 KCl, 60 KF, 10 NaCl, 2 MgCl 2 , 20 EGTA and 10 HEPES (pH 7.2) and with the extracellular solution containing (in mM): 140 NaCl,
Corresponding author e-mail: keehyun@kist.re.kr; hrhim@kist. re.kr 4 KCl, 5 glucose, 2 CaCl 2 , 1 MgCl 2 and 10 HEPES (pH 7.4) (Milligan et al. 2009 ). To assist stable seal formations, the seal enhancer containing (in mM): 80 NaCl, 3 KCl, 35 CaCl 2 , 10 MgCl 2 and 10 HEPES (pH 7.4) was used only at the seal formation step. Prior to whole-cell recordings, the external solution containing the seal enhancer was exchanged for the extracellular solution described above. Channel currents were recorded by the parallel EPC-10 patch-clamp amplifiers (HEKA Elektronik, Germany) and low-pass filtered (10 kHz) with a 4-pole Bessel filter. Cell suspension and patch solutions were automatically added onto the four recording wells in the microfabricated disposable chip (NPC-16 Chip, Nanion Technologies, Germany). Each test compound (40 µl) was applied to the patch-clamped cells via four pipette tips of NPC-16 Patchliner with a speed of 4 µl/s. Astemizole was purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan). All other chemicals were obtained from Sigma-Aldrich Corp. (St. Louis, MO, USA).
Conventional patch-clamp electrophysiology
Micropipettes were pulled from borosilicate glass capillaries (GC150T-7.5; Warner Instrument Corp., Hamden, CT, USA) on a puller (P-97; Sutter Instrument Co., Novato, CA, USA) with resistance of ~3 MΩ. Whole-cell currents were recorded with the same intracellular and extracellular solutions used for automated patch-clamp without seal enhancer. Whole-cell recordings were performed at room temperature with an EPC-10 patch-clamp amplifier (HEKA Elektronik, Germany) and low-pass filtered (10 kHz) with a 4-pole Bessel filter. Whole-cell currents were acquired and digitized at 20 kHz using the Patchmaster (HEKA Elektronik, Germany).
Data analysis
Whole-cell recordings were analyzed using the Patchmaster/Fitmaster, IGOR Pro (WaveMetrics Inc., Portland, OR, USA), and the GraphPad Prism 4 (GraphPad Software, Inc., La Jolla, CA, USA) software.
The dose-response curve was fitted to a Hill equation (sigmoidal dose-response equation),
where I min and I max are the normalized minimum and maximum currents, respectively. IC 50 is the half-maximum inhibition concentration. C is the logarithm of concentration and h is the Hill coefficient. The curve for steady-state activation was fitted to a Boltzmann sigmoidal equation
where G min and G max are the normalized minimum and maximum conductance, respectively. V 1/2-act is the mean potential for half-activation and slope act is the slope activation factor. The curve for steady-state inactivation was also fitted to a Boltzmann sigmoidal equation
where I min and I max are the normalized minimum and maximum currents, respectively. V 1/2-inact is the mean potential for half-inactivation and slope inact is the slope inactivation factor. Recovery kinetics were fitted to a double-exponential association equation
where amp is the relative amplitude, t is the time and k is the rate constant. f and s represent the fast and the slow components, respectively. The time constant (τ) is 0.69 / k. The significance of observed differences was evaluated by an ANOVA test. A p value of <0.05 was considered statistically significant. All results are presented as the means ± S.E.M.
Supplementary Results
Biophysical properties of Ca v 3.1 T-type calcium channels in automated patch-clamp were examined in a current-voltage (I-V) relationship by 50-ms test pulses from -90 to +50 mV in 5 mV-increments at a holding potential of -100 mV (Fig.  S3A) . The peak currents were normalized to the maximum peak currents and presented in normalized I (Fig. S3B) . The maximum peak currents in an I-V curve were occurred when cells were stimulated by a test pulse of -20 mV (n = 24). To examine steady-state activation properties, the channel activation curve was generated by converting currents in an I-V curve to the conductance (G) and normalizing to the maximum conductance (G / G max ), and fitted to a Boltzmann sigmoidal function (Fig. S3C) . The activation of Ca v 3.1 channels shows the mean potential for half-activation (V 1/2-act ) of -31 ± 1 mV and the slope activation factor (slope act ) of 6.1 ± 0.4 (n = 20).
To further elucidate the biophysical properties of Ca v 3.1 channels, steady-state inactivation of Ca v 3.1 channels was determined. A steady-state inactivation curve was obtained by applying a 2-s prepulse to various potentials from -105 to -40 mV and a test pulse to -20 mV at a holding potential of -100 mV (Fig. S4A) . The peak currents were normalized Figure S1 . Structures of known T-type calcium channel blockers.
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Resolution is bad for 'Verapamil' in Figure S1 . I have included another figure with a good 2-2) Figure S4A , S5A, and S8A Figures A in S4, S5, and S8 would look better if they are positioned to the top rather than t 2-3) Figure S6 Just switching alphabets B and C seems to be an easier way to fix it. But switching entire figures, not just alphabets would be better for consistency throughout Figure S3 ). relationships of peak Ca v 3.1 currents (n = 24). The peak currents were normalized to the maximum currents, and presented as normalized I, showing the maximum peak currents when evoked by a test pulse of -20 mV. C. Steady-state activation curve of Ca v 3.1 channels. The curve was produced by converting the peak currents presented in I-V curve to the conductance (G) and normalizing to the maximum conductance (G / G max ), and was fitted to a Boltzmann sigmoidal equation. The channel activation curve of Ca v 3.1 channels shows V 1/2-act = -31 ± 1 mV and slope act = 6.1 ± 0.4 (n = 20). Error bars represent S.E.M.
to the maximum peak currents (I / I max ), and the channel inactivation curve was fitted to a Boltzmann sigmoidal equation (Fig. S4B) . The mean potential of half-inactivation (V 1/2-inact ) and the slope inactivation factor in steady-state inactivation curve (slope inact ) for Ca v 3.1 channels were -79 ± 1 mV and 8.6 ± 0.7, respectively (n = 16). Steady-state inactivation properties of Ca v 3.1 channels were further examined by observing recovery from steady-state inactivation. In the recovery experiments, cells were inactivated by steps to -20 mV for 50 ms, and then tested by 50-ms steps to -20 mV with 0, 10, 20, 40, 80, 160, 320, 640, 1280 and 2560-ms intervals (Fig. S5A) . To analyze recovery kinetics, Figure S5 . Recovery from steady-state inactivation of Ca v 3.1 channels in automated patch-clamp. A. Representative whole-cell current traces of Ca v 3.1 channels evoked by 50-ms steps of -20 mV with intervals of 10, 20, 40, 80, 160, and 320 ms after 50-ms pre-pulses of -20 mV. B. Percent recovery (% Recovery) from the steady-state inactivation (n = 11). The time course of recovery from the steadystate inactivation was fitted to a double-exponential function. The time constants and the relative amplitudes of the slow (τ s and amp s ) and the fast components (τ f and amp f ) in recovery kinetics were 389 ± 156 ms, 34 ±10 and 24 ± 9 ms, 71 ± 9, respectively. Error bars represent S.E.M. the two kinetic components in recovery were obtained using a double-exponential fit (Fig. S5B ). The slow component has a time constant (τ s ) of 389 ± 156 ms with a relative amplitude (amp s ) of 34 ± 10 while the fast component shows a time constant (τ f ) of 24 ± 9 ms with a relative amplitude (amp f ) of 71 ± 9 (n = 11 and Fig. S5B ).
The biophysical parameters obtained with automated patch-clamp were compared with those determined with conventional patch-clamp (Figs. S6-S8), and summarized in Table S1 . Inactivation properties Ca v 3.1 channels such as steady-state inactivation and recovery from steady-state inactivation were similar in both methods within the experi- 20 ± 1 (77 ± 4) 24 ± 9 (71 ± 9) V max , the mean potential where maximum peak currents occur in the current-voltage curve; V 1/2-act , the mean potential for half-activation; slope act , the slope activation factor; V 1/2-inact , the mean potential for half-inactivation; slope inact , the slope inactivation factor; τ, the time constant; amp, the relative amplitude; f and s, the fast and the slow components. mental error. A slight hyperpolarizing shift was observed in the steady-state inactivation curve obtained with automated patch-clamp when compared to the conventional method, but this difference was not statistically significant (two-way repeated-measures ANOVA test, p = 0.067). However, activation properties of Ca v 3.1 channels appeared to be different between automated and conventional patch-clamp studies even under the same experimental conditions; identical cell lines and patch solutions as well as pulse protocols were used in the both experiments. In particular, the mean potential where the maximum peak currents occur (V max ), and consequently the V 1/2-act value obtained using automated Representative whole-cell currents of Ca v 3.1 channels evoked by a 50-ms step to -20 mV from a holding potential of -100 mV after 2-s pre-depolarization pulses of -110, -70 and -40 mV. B. Steady-state inactivation curve of Ca v 3.1 channels. The curve was generated by normalizing to the maximum currents (I / I max ) and presenting as a function of pre-depolarization potentials, and was fitted to a Boltzmann sigmoidal equation. The steady-state inactivation curve has V 1/2-inact = -72 ± 2 mV and slope inact = 4.0 ± 0.1 (n = 8). Error bars represent S.E.M.
Figure S7
A B patch-clamp did not recapitulate the parameters determined using conventional patch-clamp (two-way repeated-measures ANOVA test, * p < 0.05 for IV curves, *** p < 0.0001 for steady-state activation curves). The mid-point of a steadystate activation curve was shifted to more positive potentials in automated patch-clamp.
Supplementary Discussion
An apparent depolarizing shift in a steady-state activation curve of Ca v 3.1 channels was observed with automated patch-clamp when compared to the conventional method. The observed discrepancies in biophysical parameters between the two methods might result in part from the relatively small currents of the cell line used in the present study, leading to the low signal-to-noise ratio. Analyzing the data with only higher amplitude currents in automated patch-clamp would be the best way to test whether the observed differences result from the different current amplitudes. However, almost all patches obtained from automated patch-clamp exhibit the currents less than ~400 pA as shown in Fig. 2C while conventional patch-clamp provides patches with the currents in the 1~2 nA range. Thus, it is practically challenging to obtain data that have comparable current amplitudes to conventional patch-clamp data from automated patch-clamp.
Other possibilities including the difference in the setup design might account for the observed differences in biophysical properties. In the conventional patch-clamp setup for the present study, the standard polyethylene tubing is used for perfusion while the automated patch-clamp setup has a stainless steel pipette tip for drug application. Since this rigid tip is not disposable, the only way to prevent any chance of contamination is an extensive wash. Although a thorough wash was carried out after each drug application, some sticky compounds might be adsorbed to the tip during pharmacological studies, and then be released while biophysical studies were performed, thereby affecting the steady-state activation properties of Ca v 3.1 channels. Another possible influence might come from the different cell conditions for patch-clamp recordings in each setup. For conventional patch-clamp recordings, cells are attached onto the poly-Llysine coated glass cover while the automated patch-clamp setup is designed to use cell suspension. Suspended cells might exhibit different biophysical characteristics from surface-attached cells.
Most studies using automated patch-clamp have been focusing on pharmacological properties of ion channels for drug screening purposes while reports on biophysical characterization using automated patch-clamp are relatively limited. Activation properties of T-type calcium channels studied with recombinant Ca v 3.2 channels using automated patch-clamp were reported to be consistent with the values determined with conventional patch-clamp ). Interestingly, however, the different results between the conventional and automated patch-clamp systems were observed in biophysical properties of Ca v 1.2 L-type calcium channels ). The automated patch-clamp setup did not recapitulate the steady-state activation and inactivation characteristics of Ca v 1.2 channels in the presence of L-type calcium channel selective agonist, BayK8644 determined in conventional patch-clamp. These discrepancies were attributed to possible changes to patch parameters such as resistance during biophysical characterization.
Overall, the detailed characterization of biophysical properties of T-type calcium channels with automated patchclamp needs to be conducted with caution.
